Please assess the completion status of the following clinical trial:

Trial Title: 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients~* Age 18-65 years~* Eastern Cooperative Oncology Group (ECOG) status \< 2~* Surgery: R0-resection and \>= 10 removed axillary lymph nodes~* M0 by chest x-ray, bone scintigraphy and liver sonography~Exclusion Criteria:~* Polyneuropathy~* Creatinin (serum) \> 1,4 mg/dl; Bilirubin (serum) \> 2,0 mg/dl~* Cardia dysfunction, ejection fraction \< lower normal value of each institution~* Hematopoeitic insufficiency: leucocytes \< 3,5 G/l, thrombocytes \< 100 G/l~* second malignant neoplasia, except curatively treated basalioma of the skin~* Surgery before more the six weeks (42 days)~* Concurrent pregnancy; patients of childbearing potential must implement a highly effective (less than 1% failure rate) non-hormonal contraceptive measures during the study treatment~* Breast feeding woman~* Sequential breast cancer~* Reasons indicating risk of poor compliance~* Patients not able to consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- EC-Doc (Type: EXPERIMENTAL): 4 cycles epirubicin + docetaxel (90/600) i.v., q = 3 weeks, followed by 4 cycles docetaxel (100) i.v., q = 3 weeks
- CMF/CEF (Type: ACTIVE_COMPARATOR): 6 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) (600/40/600) i.v., day 1 + 8, q = 4 weeks or 6 cycles cyclophosphamide, epirubicin, 5-fluorouracil (CEF) (500/100/500) i.v., day 1, q = 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).